The Effect of Adding Vildagliptin Versus Glimepiride to Metformin on Markers of Inflammation, Thrombosis, and Atherosclerosis in Diabetic Patients With Symptomatic Coronary Artery Diseases
Phase of Trial: Phase IV
Latest Information Update: 27 Nov 2019
Price : $35 *
At a glance
- Drugs Glimepiride (Primary) ; Vildagliptin (Primary) ; Metformin
- Indications Type 2 diabetes mellitus
- Focus Biomarker; Pharmacodynamics
- 23 Nov 2019 Status changed from active, no longer recruiting to completed.
- 15 Sep 2019 Planned End Date changed from 1 Jun 2019 to 1 Jan 2020.
- 15 Sep 2019 Planned primary completion date changed from 1 Jun 2019 to 1 Dec 2019.